Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A critical analysis of the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
Read clinical reviewDeep dive into SUSTAIN-7 follow-up and extension data comparing semaglutide vs dulaglutide in type 2 diabetes, examining durability of A1C and weight effects, long-term safety signals, and what the original 40-week trial could not show.
Read clinical reviewA deep dive into the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering primary and secondary endpoint effect sizes, confidence intervals, time-course data, and response distributions.
Read clinical reviewDeep-dive into SUSTAIN-7 pre-specified and post-hoc subgroup analyses comparing semaglutide vs dulaglutide across age, sex, BMI, baseline A1C, and race in type 2 diabetes.
Read clinical reviewA deep-dive overview of the SUSTAIN-7 head-to-head RCT comparing semaglutide vs dulaglutide in type 2 diabetes, covering methodology, results, limitations, and clinical practice implications.
Read clinical reviewA deep-dive into the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, and what its results mean for real-world prescribing decisions today.
Read clinical review